PROMOT Network receives funding from EJP-RD to develop an adaptable precision medicine approach for four NMDs

We are excited to announce a successful grant application from NMD4C steering committee members Dr Cynthia Gagnon (lead investigator), Dr Hanns Lochmüller, and Dr Homira Osman for the PROMOT network: Performing a Rare Disease-Oriented Master Observational Trial to decipher complexity and optimize trial readiness. Funded by the European Joint Programme for Rare Diseases (EJP-RD), with Canadian funding contributed by the Canadian Institutes for Health Research (CIHR), the PROMOT network is a joint international collaboration involving sites across Canada, Sweden, Spain, France, Switzerland and Ireland, with a total funding amount of approximately $2 million over a 3-year period.

The PROMOT network project aims to develop a precision medicine approach that is adaptable to several rare diseases, including NMDs. Presently, a precision medicine approach requires an individual natural history study for each rare disease, with high financial and research costs associated with each study. The network’s approach will consolidate several rare NMDs into a single multi-faceted natural history study, allowing a greater number of NMDs to be studied concurrently to reduce cost-associated barriers while producing cross-validated outcome measures and improving the time to clinical trial readiness.

Combining an innovative natural history study design, adapted Master Observational Trial (MOT), and artificial intelligence (AI), the PROMOT network will respond to several unmet needs found in most rare NMDs, including prognosis and clinical trial readiness with the goals of identifying potential biomarkers amenable to treatments and providing protocols for use in clinical trials.

The PROMOT network will first develop the MOT for Oculopharyngeal Muscular Dystrophy (OPMD) alongside three neuromuscular disorders (NMDs) with shared commonalities: myofibrillar myopathies, congenital myopathies, congenital myasthenia. The MOT will then be tested in neuromuscular clinics located in Canada and internationally to document the feasibility of using this approach in rare diseases under different global health systems. To foster knowledge mobilization, the PROMOT network will create a learning and mobilization platform (LEAP FORWARD) with MDC to host clinical, physiological and behavioral outcomes data to allow insight into disease impact, which will include an interface accessible by patients and healthcare professionals.

From a neuromuscular patient and family perspective, time is one of the most important factors in disease progression; this transdisciplinary and intersectoral research project will accelerate the time to receiving a prognosis and clinical trial readiness in four NMDs. By breaking research silos within and across rare diseases, the PROMOT network’s innovative approach has the potential to reduce these delay times for patients across many more rare diseases in the future.

EJPRD

Read next...

Text reading NMD4C joins bluesky - We're now active on Bluesky! We invite you to follow us at @nmd4c.ca to stay updated on news from our Canadian neuromuscular network. NMD4C and bluesky logo, with an image of the NMD4C bluesky feed.

You Can Now Find NMD4C on Bluesky

We’re moving to Bluesky! The NMD4C will now share updates on Bluesky instead of X. Please consider following us at @nmd4c.ca to stay connected! 

CIHR Funds Interdisciplinary Project to Study SBMA in Indigenous Peoples of the Prairie Provinces The NMD4C is excited to share that network investigators Drs. Gerald Pfeffer, Alexandra King, Kerri Schellenberg, Toshifumi Yokota and Malcolm King have been awarded funding from the CIHR for an Interdisciplinary Spinal-bulbar muscular atrophy study in Indigenous peoples of the prairie provinces

CIHR Funds Interdisciplinary Project to Study SBMA in Indigenous Peoples of the Prairie Provinces

The NMD4C is excited to share that network investigators have been awarded funding from the CIHR for an Interdisciplinary Spinal-bulbar muscular atrophy study in Indigenous peoples of the prairie provinces, addressing the community needs, and developing clinical knowledge and therapies.

2025 NMD4C early career award winners profile pictures, text reading Congratulations Early Career Award Winners

NMD4C Presents the 2025 Early Career Award Recipients

We are excited to announce the recipients of the 2025 NMD4C Early Career Awards! This is the third year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.

Muscular Dystrophy Canada is thrilled to launch an innovative initiative designed to tackle the diagnostic hurdles experienced by individuals with myotonic dystrophy.

Muscular Dystrophy Canada Launches Initiative to Improve Genetic Testing Access for Myotonic Dystrophy

Muscular Dystrophy Canada is thrilled to launch an innovative initiative designed to tackle the diagnostic hurdles experienced by individuals with myotonic dystrophy.

LEARNMD content update - February 2025

New Content Available in LEARNMD

LEARNMD is the NMD4C’s online educational platform, offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide. We’re excited to share what’s new on LEARNMD in February 2025!

RQAS logo

Quebec Network Réseau Québécoise de l’Amyotrophie Spinale Joins NMD4C as Community of Practice Sub-Group

We are thrilled to announce that the RQAS, a network uniting rehabilitation clinicians across Quebec to advance the care of people with Spinal Muscular Atrophy has officially become a sub-group Community of Practice of the NMD4C